Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wick

Showing results (151-160 of 170) with videos related to

Pageof 17
Sort By:
Cancer Cell|February 13, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Nature Genetics|February 2, 2016
An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinomaYotam Drier, Matthew J Cotton, Kaylyn E Williamson, et al.
Cancer Cell|January 25, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 17, 2024
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapiesJoseph G Skeate, Emily J Pomeroy, Nicholas J Slipek, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Fusion oncoproteins and cooperating mutations define disease phenotypes in <i>NUP98</i>-rearranged leukemiaMasayuki Umeda, Ryan Hiltenbrand, Nicole L Michmerhuizen, et al.
Molecular Cancer Therapeutics|June 1, 2022
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast CancerCraig Furman, Xiaoling Puyang, Zhaojie Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017Mary B Daly, Robert Pilarski, Michael Berry, et al.
Mayo Clinic Proceedings|March 6, 2016
Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic ExperienceKonstantinos N Lazaridis, Kimberly A Schahl, Margot A Cousin, et al.
Blood|July 23, 2025
Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged LeukemiaMasayuki Umeda, Ryan Lea Hiltenbrand, Nicole L Michmerhuizen, et al.
Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.
Pageof 17

Showing results (151-160 of 170) with videos related to

Sort By:
Pageof 17
Cancer Cell|February 13, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Nature Genetics|February 2, 2016
An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinomaYotam Drier, Matthew J Cotton, Kaylyn E Williamson, et al.
Cancer Cell|January 25, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 17, 2024
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapiesJoseph G Skeate, Emily J Pomeroy, Nicholas J Slipek, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Fusion oncoproteins and cooperating mutations define disease phenotypes in <i>NUP98</i>-rearranged leukemiaMasayuki Umeda, Ryan Hiltenbrand, Nicole L Michmerhuizen, et al.
Molecular Cancer Therapeutics|June 1, 2022
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast CancerCraig Furman, Xiaoling Puyang, Zhaojie Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017Mary B Daly, Robert Pilarski, Michael Berry, et al.
Mayo Clinic Proceedings|March 6, 2016
Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic ExperienceKonstantinos N Lazaridis, Kimberly A Schahl, Margot A Cousin, et al.
Blood|July 23, 2025
Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged LeukemiaMasayuki Umeda, Ryan Lea Hiltenbrand, Nicole L Michmerhuizen, et al.
Science Signaling|October 11, 2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Emiliano Cocco, F Javier Carmona, Pedram Razavi, et al.
Pageof 17